How did the cancellation affect MRK and NEUP stocks?

MRK fell 2.3% and NEUP fell 8.1% in after-hours trading.

Merck Scraps Another Alzheimer's Drug Trial Under Neuphoria Partnership

Q: Is this the first time Merck has canceled an Alzheimer's drug trial under the Neuphoria partnership?

No, this is the second cancellation under the partnership, following a previous one last year.

Merck has discontinued an Alzheimer's drug trial under its partnership with Neuphoria, citing business reasons, leading to declines in both MRK and NEUP stocks.

July 2, 2026

2 min read

Source: Stocktwits

Merck (MRK) announced the discontinuation of an investigational Alzheimer's disease drug trial under its partnership with Neuphoria (NEUP), citing business reasons. The decision sent MRK shares down 2.3% and NEUP shares down 8.1% in after-hours trading.

Discontinuation Details

Merck stated that the decision was based on business reasons, without providing further details on the drug's efficacy or safety. This marks the second Alzheimer's drug trial cancellation under the partnership, following a previous discontinuation last year.

Context

Pharmaceutical companies face significant challenges in developing effective Alzheimer's treatments, with many clinical trials failing to show positive results. The move comes as Merck reassesses its research priorities.

What It Means for Investors

The cancellation is a setback for investors hoping for a breakthrough in Alzheimer's treatment, but it may allow Merck to focus on more promising therapeutic areas. Investors should monitor future announcements regarding the company's pipeline.

Frequently Asked Questions

Merck cited business reasons for the discontinuation without providing further details.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.